AMH Equity Ltd Buys New Position in Orchestra BioMed Holdings, Inc. $OBIO

AMH Equity Ltd bought a new stake in Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 166,000 shares of the company’s stock, valued at approximately $412,000. AMH Equity Ltd owned approximately 0.43% of Orchestra BioMed at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd bought a new position in shares of Orchestra BioMed during the 2nd quarter worth $31,000. Creative Planning purchased a new position in shares of Orchestra BioMed during the 2nd quarter valued at about $40,000. XTX Topco Ltd purchased a new position in Orchestra BioMed in the 2nd quarter worth $45,000. Jane Street Group LLC bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at about $50,000. Finally, Bank of America Corp DE raised its holdings in Orchestra BioMed by 35.7% during the 2nd quarter. Bank of America Corp DE now owns 21,577 shares of the company’s stock valued at $58,000 after buying an additional 5,678 shares during the last quarter. Institutional investors and hedge funds own 53.20% of the company’s stock.

Orchestra BioMed Price Performance

Shares of Orchestra BioMed stock opened at $4.22 on Friday. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.73 and a quick ratio of 4.72. The business has a 50 day simple moving average of $4.48 and a two-hundred day simple moving average of $3.50. The stock has a market capitalization of $238.30 million, a P/E ratio of -2.32 and a beta of 0.63. Orchestra BioMed Holdings, Inc. has a 12 month low of $2.20 and a 12 month high of $6.16.

Orchestra BioMed (NASDAQ:OBIO) last posted its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Orchestra BioMed had a negative net margin of 2,665.05% and a negative return on equity of 320.09%. The company had revenue of $0.86 million during the quarter, compared to analyst estimates of $0.74 million. As a group, analysts predict that Orchestra BioMed Holdings, Inc. will post -1.66 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on OBIO shares. Cowen initiated coverage on shares of Orchestra BioMed in a research report on Wednesday, December 10th. They set a “buy” rating on the stock. Barclays raised their price objective on shares of Orchestra BioMed from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. TD Cowen assumed coverage on Orchestra BioMed in a research report on Wednesday, December 10th. They issued a “buy” rating and a $15.00 price objective on the stock. Chardan Capital restated a “buy” rating and set a $20.00 price target on shares of Orchestra BioMed in a report on Thursday, November 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Orchestra BioMed in a research note on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Orchestra BioMed currently has a consensus rating of “Moderate Buy” and a consensus target price of $13.80.

Orchestra BioMed Company Profile

Orchestra BioMed, Inc (NASDAQ: OBIO) is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company’s research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed’s pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.

Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.